54. Asparlas

Servier
(Servier)

Active ingredient: calaspargase pegol
Disease: acute lymphoblastic leukemia
Approved: Dec. 20
Peak sales: $200 million+
Company: Servier

The scoop: As Takeda eyed Shire for a massive buyout earlier this year, Shire inked a $2.4 billion deal to sell its oncology outfit to France's Servier. Now, Servier has secured FDA approval for an acute lymphoblastic leukemia (ALL) drug picked up in the buyout, Asparlas. The drug is designed to be a longer-acting version of Oncaspar, which Servier also acquired in the purchase. The FDA approved Asparlas in December to treat ALL patients aged 1 month to 21 years. A previous investor presentation from Baxalta tagged the drug as a key program that could generate more than $200 million. Baxalta merged with Shire in 2016. Shire's oncology business generated $262 million in 2017 before the company offloaded the oncology assets to Servier. — Eric Sagonowsky

54. Asparlas

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.